Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
73°
Clear
Site search
Search
Menu
Subscribe
Home
News
Local News
Sports
Obituaries
Photos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Explore the Sheyenne
Best of 2023
Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Alzamend Neuro Inc
(NQ:
ALZN
)
3.080
-0.310 (-9.14%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Alzamend Neuro Inc
< Previous
1
2
3
4
5
6
7
8
9
Next >
Alzamend Neuro Receives FDA “Study May Proceed” Notification for a Phase IIA Clinical Trial of AL001, a Next‑Generation Lithium Therapeutic Drug Candidate, in Major Depressive Disorder Patients
November 20, 2023
From
Alzamend Neuro, Inc.
Via
Business Wire
EXCLUSIVE: Alzamend Neuro Receives FDA Go-Ahead Letter For Mid-Stage Major Depressive Disorder Study
November 20, 2023
Alzamend Neuro Inc (NASDAQ: ALZN) has received a "Study May Proceed" letter from the FDA for the initiation of study AL001-MDD01, a Phase 2A clinical study of AL001 for
Via
Benzinga
Exposures
Product Safety
EXCLUSIVE: Alzamend Neuro Seeks FDA Approval For Mid-Stage PTSD Study With Next‑Gen Lithium Therapeutic Drug Candidate
November 13, 2023
Alzamend Neuro Inc (NASDAQ: ALZN) has submitted an investigational new drug (IND) application to the FDA for the initiation of study AL001-PTSD01, a Phase 2A plasma/brain pharmacokinetics study of...
Via
Benzinga
Exposures
Product Safety
Why Ault Alliance Are Rocketing Today
July 12, 2023
Ault Alliance Inc (AMEX: AULT) shares are trading exponentially higher by over 147% after the company stated that
Via
Benzinga
Alzamend Neuro Regains Compliance with Nasdaq’s Minimum Bid Price Requirement
November 16, 2023
From
Alzamend Neuro, Inc.
Via
Business Wire
12 Health Care Stocks Moving In Wednesday's After-Market Session
November 08, 2023
Via
Benzinga
Alzamend Neuro Submits IND Application for a Phase IIA Clinical Trial in Post-Traumatic Stress Disorder Patients of Next‑Generation Lithium Therapeutic Drug Candidate AL001
November 13, 2023
From
Alzamend Neuro, Inc.
Via
Business Wire
Dow Surges Over 500 Points; Western Digital Announces Plan To Split Into Two Companies
October 30, 2023
U.S. stocks traded higher toward the end of trading, with the Dow Jones index gaining more than 500 points on Monday. The Dow traded up 1.67% to 32,959.68 while the NASDAQ rose 1.25% to 12,800.95. The...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Why ON Semiconductor Shares Are Trading Lower By Around 18%? Here Are Other Stocks Moving In Monday's Mid-Day Session
October 30, 2023
Gainers Miromatrix Medical Inc. (NASDAQ: MIRO) shares climbed 230.7% to $3.3401 after United Therapeutics agreed to acquire the company for $3.25 per share in cash.
Via
Benzinga
Crude Oil Falls Over 3%; Miromatrix Medical Shares Spike Higher
October 30, 2023
U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining more than 100 points on Monday. The Dow traded up 1.14% to 32,788.73 while the NASDAQ rose 0.98% to 12,766.33. The...
Via
Benzinga
Topics
Stocks
Exposures
Fossil Fuels
US Equities
Why Alzamend Neuro (ALZN) Stock Is Nosediving Today
October 30, 2023
Alzamend Neuro Inc (NASDAQ: ALZN) shares are trading lower by 31.2% to $0.12 Monday morning after the company announced a reverse stock split. What Happened?
Via
Benzinga
Nasdaq Gains Over 1%; McDonald's Reports Upbeat Earnings
October 30, 2023
U.S. stocks traded higher this morning, with the Dow Jones index gaining more than 250 points on Monday. Following the market opening Monday, the Dow traded up 0.85% to 32,695.89 while the NASDAQ rose...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Alzamend Neuro Announces Reverse Stock Split
October 30, 2023
From
Alzamend Neuro, Inc.
Via
Business Wire
Alzamend Neuro Submits IND Application for a Phase IIA Clinical Trial in Major Depressive Disorder Patients of its Next‑Generation Lithium Therapeutic Drug Candidate AL001
October 23, 2023
From
Alzamend Neuro, Inc.
Via
Business Wire
EXCLUSIVE: Alzamend Neuro Submits IND For Phase IIA Trial Of Next-Gen Lithium Candidate In Major Depressive Disorder
October 23, 2023
Alzamend Neuro Inc (NASDAQ: ALZN) has submitted an investigational new drug (IND) application to the FDA to initiate AL001-MDD01, a Phase IIA plasma/brain pharmacokinetics clinical study of AL001 for...
Via
Benzinga
Exposures
Product Safety
Alzamend Neuro Receives FDA “Study May Proceed” Notification for a Phase IIA Clinical Trial of AL001, a Next-Generation Lithium Therapeutic Drug Candidate, in Bipolar Disorder Patients
October 02, 2023
From
Alzamend Neuro, Inc.
Via
Business Wire
EXCLUSIVE: Alzamend Neuro To Start Next-Gen Therapy Study For Bipolar Disorder
October 02, 2023
Alzamend Neuro Inc (NASDAQ: ALZN) received the FDA's "Study May Proceed" letter to initiate study AL001-BD01, a Phase 2A clinical study of AL001 for bipolar disorder type 1. The company expects the...
Via
Benzinga
NetSol Technologies And 2 Other Stocks Under $2 Insiders Are Buying
September 27, 2023
The Dow Jones closed lower by around 388 points on Tuesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Alzamend Neuro Granted Extension by Nasdaq Panel to Regain Compliance with the Minimum Bid Price Continued Listing Requirement
September 22, 2023
From
Alzamend Neuro
Via
Business Wire
12 Health Care Stocks Moving In Wednesday's After-Market Session
September 20, 2023
Via
Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
September 08, 2023
Via
Benzinga
Alzamend Neuro Submits IND Application for Phase IIA Clinical Trial of AL001, a Next-Generation Lithium Therapeutic Drug Candidate, in Bipolar Disorder Patients
August 30, 2023
From
Alzamend Neuro
Via
Business Wire
EXCLUSIVE: Alzamend Seeks FDA Approval For Study For Upgraded Version Of Most Commonly Used Treatment For Bipolar Disorder
August 30, 2023
Alzamend Neuro Inc (NASDAQ: ALZN) has submitted an investigational new drug (IND) application to the FDA to initiate AL001-BD01, a Phase 2A study of AL001 for bipolar disorder.
Via
Benzinga
Exposures
Product Safety
12 Health Care Stocks Moving In Tuesday's After-Market Session
August 15, 2023
Via
Benzinga
FDA Approves Biogen's Alzheimer's Drug: Here Are Other Companies With Treatments In The Pipeline
July 07, 2023
The FDA fully approved Biogen Inc.’s (NASDAQ: BIIB) Alzheimer’s treatment Leqembi on Thursday, becoming the first Alzheimer’s antibody treatment to reach full approval.
Via
Benzinga
EXCLUSIVE: Alzamend Neuro Identifies Potential AL001 Dose Level For Upcoming Alzheimer's Study
June 22, 2023
Alzamend Neuro Inc (NASDAQ: ALZN) has identified a maximum tolerated dose (MTD) for developing AL001 from a multiple-ascending dose study as assessed by an independent safety review committee.
Via
Benzinga
Why Yext Shares Are Trading Higher By 14%; Here Are 20 Stocks Moving Premarket
June 07, 2023
Gainers
Via
Benzinga
Alzamend Neuro Announces Positive Phase IIA Clinical Trial Results for AL001
June 22, 2023
From
Alzamend Neuro
Via
Business Wire
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
June 07, 2023
We're starting the day off right with a breakdown of the biggest pre-market stock movers worth reading about on Wednesday!
Via
InvestorPlace
Alzamend Neuro CEO Stephan Jackman to Participate on the “Mental Health, More Critical Than Ever” Panel at the Maxim Group’s Virtual Healthcare Conference
June 13, 2023
From
Alzamend Neuro
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
9
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.